In the pivotal clinical trials that led to Rybelsus's approvalincluding the PIONEER programmeUTIs were not reported at a significantly higher rate in patients taking semaglutide compared with those on placebo or comparator treatments, according to the European Public Assessment Report (EPAR)
Data collection Data was collected from the electronic medical record on demographics including age, sex, race, and ethnicity
He, X., Guan, H., Liang, W., Huang, Z., Xu, L., Zhang, P., et al
Free of artificial colours, preservatives, and sweeteners